Viral Gene Transfer of the Antiapoptotic Factor Bcl-2 Protects Against Chronic Postischemic Heart Failure

Subhasis Chatterjee, MD; Allan S. Stewart, MD; Lawrence T. Bish, BA; Vasant Jayasankar, MD; Elizabeth M. Kim, BS; Timothy Pirolli; Jeffrey Burdick, BS; Y. Joseph Woo, MD; Timothy J. Gardner, MD; H. Lee Sweeney, PhD

Background—Apoptosis secondary to acute ischemia and chronic remodeling is implicated as a mediator of heart failure. This study was designed to assess the effect of in vivo viral gene transfer of the anti-apoptotic factor Bcl-2 to block apoptosis and preserve ventricular geometry and function.

Methods and Results—In a rabbit model of regional ischemia followed by reperfusion, an experimental group treated with adeno-Bcl-2 was compared with a control group receiving empty vector adeno-null. Function was assessed by echocardiography, and sonomicrometry of the border zone was compared with the normal left ventricle (LV). Animals were killed at 6 weeks, and an additional group was killed after 3 days to see whether virus administration conferred an immediate effect. Animals that were administered Bcl-2 maintained higher ejection fractions at 2, 4, and 6 weeks compared with controls. Sonomicrocrystals demonstrated greater protection of border zone fractional shortening at 6 weeks. The Bcl-2 group had superior preservation of LV geometry with less ventricular dilatation and wall thinning. There was also reduced apoptosis compared with the controls. Finally, in the animals killed at 3 days, no functional difference was observed between the Bcl-2 and control groups.

Conclusions—Gene transfer of Bcl-2 preserves LV function after ischemia despite the absence of an observed acute protective effect. The benefit at 6 weeks is postulated to result from a Bcl-2–mediated reduction in apoptosis and ventricular remodeling. Adeno–Bcl-2 administration offers a potential strategy to protect the heart from late postischemic heart failure. (Circulation. 2002;106[suppl I]:I-212-I-217.)

Key Words: apoptosis • gene therapy • heart failure • myocardial infarction • remodeling

Ventricular injury after myocardial infarction can lead to progressive chamber enlargement. This change occurs in concert with a corresponding decline in ventricular function. As the injured ventricle dilates, there is a failure to maintain a compensatory proportional increase in wall thickness. Consequently, the ratio of wall thickness to chamber radius is not preserved, and the transition to decompensated ventricular hypertrophy occurs. Not only does this thinning of the ventricular wall occur in the infarcted necrotic zone, but it has also been demonstrated in the border zone region between the ischemic segment and the nonischemic viable myocardium. The interaction of the area of infarction with the remaining viable myocardium results in supraphysiologic stretch across the border zone, which augments the tension load. As a result of the heightened wall tension, the ventricle begins to remodel and to undergo dilatation.

Initially, attempts to explain this expansion focused on analyzing length changes in individual myocytes or determining variability in the collagen content of the extracellular matrix. However, it became apparent that the increase in wall tension, changes in wall dimensions, and further ventricular dilatation could result from the side-to-side slippage of myocytes from one another in an effort by these myocytes to distribute themselves to cover a larger ventricle, a phenomenon known as cell-cell slippage. Recent work has suggested that lateral slippage of myocytes is an early event that may condition the onset, development, and progression of a dilated cardiomyopathy that evolves after an acute myocardial infarction. Moreover, it has recently been demonstrated that cell loss within the myocardium may further destabilize the ventricular scaffolding, resulting in this cell-cell slippage of the remaining myocytes.

This cell loss may be secondary to apoptosis or programmed cell death. Myocardial apoptosis has been demonstrated in animal models and humans after ischemia/reperfusion injury, myocardial infarction, congestive heart failure, and ischemic cardiomyopathy. Human autopsy data have revealed evidence of apoptosis within the infarct border zone.
but not in other remote areas of the heart outside the infarct. It appears that apoptosis is an ongoing process associated with cardiac remodeling in the diseased heart. However, data are inconclusive in correlating the presence of apoptosis to cardiac pathophysiology and ventricular dysfunction.

Both proapoptotic and antiapoptotic factors exist simultaneously in the cell environment, and the balance between cell death and survival is mediated by a convergence of these factors. Apoptosis appears to be a universal mechanism by which organisms eliminate damaged or unnecessary cells. The apparent benefit of the energy-requiring process of apoptosis as opposed to cellular necrosis is that injured cells do not release their intracellular contents, which would result in adjacent cell injury and trigger an inflammatory response. It is likely that ischemic myocytes undergo apoptosis at a relatively early stage long before the onset of necrosis. It is unknown, however, whether the stimulus for the cell to initiate apoptosis is a sign of irreversible damage to cellular integrity. Blocking apoptosis in such a cell may theoretically prove to be detrimental, since the cell may instead go on to necrosis instead of apoptosis. On the other hand, it may be that blocking apoptosis prevents cell death.

The mitochondria play a critical role in apoptosis. The cytochrome c step in the electron transport chain is the most vulnerable to disruption. When a breakdown occurs, cytochrome c is released from the mitochondria into the cytosol to form a complex with the apoptosis activating factor (Apaf-1) and procaspase-9. Caspases are a family of cysteine proteases, and some are implicated as mediators of apoptosis. Synthesized as inactive precursors, they are proteolytically cleaved at specific aspartate residues into their active form. Thus, the cytochrome c/Apaf-1/procaspase-9 complex activates caspase-9, which in turn activates other effector caspases, resulting in programmed cell death.

One antiapoptotic factor, Bcl-2, has the potential to block apoptosis. The Bcl-2 protein family derives its name from B-cell lymphoma, where it was originally discovered. It is a potent and well-characterized regulator of cell survival. This 28-kDa protein is localized on the mitochondrial outer membrane, and it is ideally positioned to control cell survival at an early point in the apoptotic pathway. It binds to and inactivates the Bax protein by preventing the formation of Bax heterodimers that disrupt mitochondrial membrane integrity. Blocking apoptosis in such a cell may theoretically prove to be detrimental, since the cell may instead go on to necrosis instead of apoptosis. On the other hand, it may be that blocking apoptosis prevents cell death.

In this study, we proposed to administer adeno-Bcl-2 after a period of myocardial ischemia to determine its role in preventing the development of posts ischemic heart failure. The hypothesis of this study is that chronic, progressive ventricular dilatation and dysfunction seen after myocardial ischemia may be exacerbated by apoptosis in the surviving myocyte pool. After the initial ischemia and reperfusion injury, immediate cell death occurs in the infarcted zone, mostly by necrosis with some apoptosis. As the ventricle remodels and the infarction proceeds to stiffen, we postulate that apoptosis persists at a low level in the border zone. Continued cell death and the loss of myocytes in this region may lead to ventricular dilatation and dysfunction. As a result, blocking apoptosis may reduce the drive toward continued ventricular dilatation and preserve myocardial function. This would allow targeted gene therapy to be an adjunct to standard therapies after infarction in an effort to prevent subsequent heart failure.

Methods

Animal Care

This study was performed in accordance with the animal care guidelines of the Institutional Animal Care and Use Committee of the University of Pennsylvania.

Adenoviral Vector Construction

A replication-deficient (E1, E3 deleted) adenoviral vector containing the transgene encoding human Bcl-2 and the constitutively active cytomegalovirus (CMV) promoter was obtained from the University of Iowa Vector Core.

Animal Surgery

Thirty New Zealand White rabbits (3 to 4 kg) were used in the study. All rabbits were fully anesthetized with intramuscular doses of ketamine (40 mg/kg), xylazine (2.5 mg/kg), glycopyrrolate (0.02 mg/kg), and buprenorphine (0.05 mg/kg) and then mechanically ventilated (Hallowell EMC model 2000). The left hemithorax was opened through the third intercostal space, exposing the base of the heart. The circumflex artery was identified, and a 6-0 polypropylene suture was placed around its circumference at a point halfway between the atrioventricular groove and the left ventricular (LV) apex. The circumflex tourniquet was tightened to achieve complete cessation of flow as demonstrated by both electrocardiographic changes and visual blanching of the myocardium. After 30 minutes, the tourniquet was released, allowing for reperfusion.

Next, the main pulmonary artery and ascending aorta were each dissected free and encircled with a 0-4 silk suture. Each silk tie was passed through a 14F red rubber catheter creating a tourniquet. The pulmonary tourniquet was then tightened for complete pulmonary artery occlusion. The LV was allowed to empty for 5 seconds, and then the aortic tourniquet was tightened to achieve complete aortic occlusion. A solution (1000 μL) containing 5.0×10⁹ particle-forming units of recombinant human adenovirus Bcl-2 suspended in 10% glycerol, was injected into the LV cavity in the experimental group (n=11). The control group (n=7) received 1000 μL of a solution containing 5.0×10⁹ particle-forming units of empty vector adeno-null. After 30 seconds of complete outflow occlusion, the tourniquets were removed. The chest was closed, and the animal recovered without operative intervention for 6 weeks. During this interval, the animal was studied with transthoracic echocardiography at 2-week intervals (weeks 2, 4, and 6).

The animals returned for nonsurvival surgery after 6 weeks. A repeated left thoracotomy was performed with exposure of the LV free wall. A polypropylene suture that marked the site of circumflex artery occlusion identified the border zone. Four 1-mm piezoelectric sonomicrocrystals were implanted into the myocardium to measure fractional shortening. This included the placement of 2 crystals in the infarcted region and 2 crystals in the normal LV away from the infarcted region. (Figure 1) After sonomicrometry, the heart was arrested in diastole by an intravenous injection of 1 mL KCl (1 mM/mL), and the right atrium was incised to allow drainage of blood. The heart was procured, and the LV cavity was filled with OCT embedding compound retrograde through the transsected aortic root at a constant intracavitary pressure. The catheter was removed and the aortic root was ligated. The heart was placed in a container of OCT embedding compound, bathed in isopentane, frozen in liquid nitrogen, and stored at −80°C.
Figure 1. Representative composite intraoperative photograph, which demonstrates the circumflex artery tourniquet positioned on the left ventricle for regional ischemia. In addition, it illustrates the position of the 2 sonomicrometers within the ischemic segment (“IN” position) 10 mm apart from each other, and the 2 sonomicrometer crystals within the viable myocardium outside the infarct zone (”OUT” position) 10 mm apart. Fractional shortening is defined as the difference between the end-diastolic length and the end-systolic length divided by the end-diastolic length (the distance between the crystals). Contractility across the border zone was measured by assessing segmental length changes between a crystal in the “IN” position with the ipsilateral (in relation to the tourniquet site of occlusion) “OUT” crystal 10 mm apart. Normal contractility was measured between the 2 “OUT” crystals.

An additional group of 6 rabbits (n = 2, Bcl-2; n = 3, adeno-null) underwent the identical surgical procedure but were killed on postoperative day 3 after sonomicrometry and echocardiography. The heart was arrested in diastole with 1 mL of KCl (1 mEq/1 mL) and procured as previously described. This group was used to determine whether Bcl-2 administration would demonstrate an effect immediately within 3 days or whether it would be apparent over time. In addition, a group of normal rabbits (n = 5) was killed without intervention to determine baseline ventricular wall thickness and diameter. There was 1 death during the procedure from ventricular dysrhythmia and 1 death in the follow-up period (2/30, or 6.7% total mortality).

Functional Analysis and Assessment of Infarct Percentage

Functional analysis was studied by transthoracic echocardiography to evaluate global cardiac function. Each animal underwent echocardiography at 2, 4, and 6 weeks after surgery under light sedation (ketamine/xylazine). The group that was killed after 3 days underwent echocardiography before euthanasia. Five normal rabbits were studied to determine baseline ejection fraction (EF). Each of the investigators and an echocardiography specialist were blinded to the treatment groups.

Sonomicrometry, a well-established technique that measures LV segmental length changes during each cardiac cycle, was used to measure regional contractility. Contractility across the border zone was measured between a crystal in the infarcted region and the ipsilateral (in relation to the tourniquet site of occlusion) crystal 10 mm apart in the viable myocardium. Normal contractility was measured between the 2 crystals in the infarcted region and the end-systolic length divided by the end-diastolic length (the distance between the crystals). Fractional shortening is defined as the difference between the end-diastolic length and the end-systolic length divided by the end-diastolic length (the distance between the crystals). The data were analyzed with Sonoview software (Sonometrics Corp.) and reported as a percentage of baseline±SEM.

Four sections from each heart were analyzed for infarct percentage. The area was stained with Coomassie blue, and the actin band was identified to confirm equal loading conditions.

Western Blotting

Specimens obtained for Western blotting were snap-frozen in liquid nitrogen after removal from the animal, without OCT fixative. Specimens were pulverized, homogenized in 10 volumes of sodium dodecyl sulfate (SDS) lysis buffer (100 mmol/L Tris, pH 8.0; 10% SDS, 10 mmol/L EDTA, 50 mmol/L dithiothreitol), and sheared with a 25-gauge needle. Samples were normalized for total protein content, and 50 μg of each sample was electrophoresed on a 12.5% SDS-polyacrylamide gel after addition of 6X sample loading buffer and 3 minutes of denaturation at 100°C. Proteins were then transferred to Immobilon-P (Millipore) by using a wet transfer apparatus. The membrane was subsequently blocked with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween-20. Immunoblotting was performed using the mouse monoclonal antibody against human Bcl-2 at a 1:100 dilution (DAKO). Detection was performed using the ECL kit (Amersham). Subsequently, the Immobilon-P membrane was stained with Coomassie blue, and the actin band was identified to confirm equal loading conditions.

Statistical Analysis

All data were expressed as mean value±SEM. Statistical analyses were performed using INSTAT® (GraphPad Software). The un-
paired, 2-tailed Student’s t test was used to calculate the probability value. Multiple comparisons against the control were first analyzed by 1-way analysis of variance followed by Tukey-Kramer’s modified unpaired student’s t test to determine significance between groups. A probability value <0.05 was considered significant.

**Results**

**Western Blot**

At 6 weeks, increased expression of Bcl-2 was demonstrated in the adeno-Bcl-2–treated group compared with the controls (Figure 2).

**Echocardiography**

At 3 days, no difference in EF was observed in the Bcl-2–treated group compared with the controls (33 ± 2.5% versus 31 ± 6.0%; P = NS). However, Bcl-2 animals maintained a higher EF than controls at week 2 (41 ± 1.8% versus 32 ± 1.5%, P < 0.05), week 4 (41 ± 2.0% versus 29 ± 2.0%, P < 0.01), and week 6 (40 ± 1.8% versus 27 ± 1.8%, P < 0.001) as shown in Figure 3. For comparison, baseline EF in a group of native rabbits was 42 ± 1.2% (P = NS compared with Bcl-2).

**Sonomicrometry**

At 3 days, there was no statistical difference in fractional shortening seen in the Bcl-2–treated groups compared with the controls (Bcl-2, 50.4 ± 7.6% versus control, 62.2 ± 13.8%; P = NS). However, at 6 weeks, there was significantly greater preservation of fractional shortening in the Bcl-2 group (Bcl-2, 72.1 ± 7.0% versus control, 49.8 ± 2.0%; P < 0.03). Results are depicted in Figure 4. Echocardiography and sonomicrometry together consistently demonstrated greater preservation of myocardial contractility in the Bcl-2–treated animals.

**Infarct Size**

There was no difference in the infarct size in the Bcl-2 group (28.3 ± 2.7%) compared with the control group (28.6 ± 2.0%, P = NS).

**Ventricular Geometry**

Control rabbits had significant ventricular dilatation with a greater mean LV midchamber diameter (16.87 ± 0.67 mm) compared with the uninfarcted and untreated native rabbits (13.44 ± 0.56 mm, P < 0.01). There was significant wall thinning in the control group (2.57 ± 0.15 mm) compared with native rabbits (3.61 ± 0.60 mm, P < 0.001). On the other hand, rabbits treated with adeno-Bcl-2 showed no statistically significant difference from native rabbits with respect to ventricular diameter (13.70 ± 0.46 mm, P = NS) or mean free-wall thickness (3.34 ± 0.10 mm, P = NS). In addition, there was significant preservation of chamber dilatation (P < 0.01) and free-wall thickness (P < 0.01) in the Bcl-2 group compared with controls. The results are summarized in Figures 5 and 6. A representative cross section from the border zone from each group is shown in Figure 7.

**Demonstration of Apoptosis**

There was a significant reduction in the apoptotic index in the Bcl-2 group compared with the controls after 6 weeks (control, 2.77 ± 0.35% versus Bcl-2, 1.01 ± 0.14%; P < 0.0002). The results are shown in Figure 8.

**Discussion**

Myocardial cell death after infarction results in progressive ventricular dilatation. Olivetti et al noted a 20% increase in midchamber luminal diameter and a 33% thinning of the ventricular wall in a rat ischemia model consisting of a 63% infarction in the area at risk. This is consistent with the results observed in our 30% total LV infarction model. This study
demonstrates a protective effect of Bcl-2 with respect to preservation of ventricular geometry and prevention of ventricular dilatation. This was paralleled by superior preservation of ventricular function over time.

In addition to a significant number of myocytes undergoing apoptosis in the ischemic segment during the initial period of ischemia/reperfusion, it appears that apoptosis is present at the border zone beyond the initial injury. Although the TUNEL assay is not specific for cardiomyocytes, recent reports have determined that nearly all apoptotic bodies are cardiomyocytes. Olivetti et al. also noted that the mechanism of ventricular wall thinning of the remaining myocardium was the result of a 36% reduction in the mural number of myocytes over time. Initial myocyte loss may be coupled with additional cell loss over time due to apoptosis.

The pathophysiological contribution of chronic apoptosis is suggested by the comparison of ventricular function at 3 days to 6 weeks. Since Bcl-2 overexpression would first be detected 48 to 72 hours after viral gene delivery, we would not expect to see an immediate difference in function, since the ischemia/reperfusion injury and infarct size are largely determined in the first 24 hours. This is supported by the data noting that at 3 days after ischemia, there is no functional difference between the groups treated with Bcl-2 or adeno-null. In addition, there was no difference in infarct size between the 2 groups, since Bcl-2 would not have had a chance to exert an immediate protective effect. However, the benefit over the course of the next 6 weeks seen in the Bcl-2 group would be from preventing a slow decline in function by blocking apoptosis that occurs after the initial injury.

The trigger for apoptosis over the chronic period may be due to stretch across the border zone. Pathological alterations of myocardial load as seen after infarction may be coupled with the generation of reactive oxygen species and the activation of gene products implicated in apoptosis. There is evidence to suggest that progressive stretch leads to an increase in cytosolic calcium levels, which destabilize the mitochondrial membrane and trigger the release of cytochrome c and apoptosis. In addition, stretch sensors within the affected cells signal autocrine release of angiotensin II, which subsequently activates the transcription factor p53, favoring apoptosis by increasing Bax and decreasing Bcl-2 expression. Thus, as the mechanical disadvantage of higher wall tension is augmented with infarct maturation, ventricular stiffening, and progressive chamber dilatation, the continued stretch across the border zone may initiate and sustain further apoptosis.

Although this stretch may be a trigger of apoptosis, other initiators of apoptosis may be present. Tumor necrosis factor-α (TNF-α) has been demonstrated to be present in increased levels in congestive heart failure, myocardial infarction, and ischemia/reperfusion injury. TNF-α has been shown to trigger apoptosis as well by activation of caspase-8. In addition, pathological alterations in the border zone may occur because the oxygenation potential of the surviving myocardium is significantly reduced in this region, making the cells more susceptible to additional ischemic episodes. Bcl-2 conferred protection from apoptosis during the entire 6 weeks examined while gene expression was maintained. It would be important to determine whether this protective effect of Bcl-2 would still be present over a longer period once the transgene was no longer expressed. It may be that further long-term protection requires continued Bcl-2 expression; on the other hand, it may be that Bcl-2 is only required

Figure 5. Assessment of left ventricular dilatation, measured by ventricular diameter at the border zone (*P<0.01 when compared with adeno-null control group; #P=NS and H10P<0.01 when compared with native group).

Figure 6. Assessment of left ventricular (LV) free-wall thinning at the border zone was measured by LV free-wall thickness (*P<0.01 when compared with adeno-null control group, #P=NS and H10P<0.01 when compared with native group).

Figure 7. Representative sections at border zone. Representative midchamber sections through the border zone 6 weeks after ischemia are depicted above. The section on the left is a native (uninfarcted and untreated) rabbit heart. The section in the middle is a null control heart (no Bcl-2), and the section on the right is a heart transfected with adeno-Bcl-2. There is a significant increase in midchamber transverse diameter and decrease in wall thickness in the untreated infarcted group compared with the infarcted Bcl-2-treated group and native group.
Figure 8. Apoptotic index. A significant reduction in the percentage of apoptotic cells in the Bcl-2 group compared with the controls (*P<0.0002) after 6 weeks is demonstrated.

during a critical period soon after the infarction to “rescue” the heart by blocking apoptosis.

We postulate that apoptosis persists within the border zone region after infarction, which contributes to eventual ventricular dilatation and dysfunction. The data suggest that blocking apoptosis in this region can prevent pathological ventricular remodeling. Administration of adenov-Bcl-2 leads to a reduction in apoptosis, preservation of ventricular geometry, and prevention of postischemic heart failure.

Acknowledgments

The authors acknowledge the University of Iowa Gene Transfer Vector Core for the Bcl-2 adenoaviral vector preparation. This work was supported by grants (HL07843 and HL59407) from the National Heart, Lung, and Blood Institute, National Institutes of Health.

References


Viral Gene Transfer of the Antiapoptotic Factor Bcl-2 Protects Against Chronic Postischemic Heart Failure
Subhasis Chatterjee, Allan S. Stewart, Lawrence T. Bish, Vasant Jayasankar, Elizabeth M. Kim, Timothy Pirolli, Jeffrey Burdick, Y. Joseph Woo, Timothy J. Gardner and H. Lee Sweeney

Circulation. 2002;106:I-212-I-217
doi: 10.1161/01.cir.0000032907.33237.55
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/106/12_suppl_1/I-212

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/